Join
Live feed
·
PRReleasevia Quantisnow
Ligand Pharmaceuticals Incorporated logo
Travere Therapeutics Inc. logo

Ligand's Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy

ByQuantisnow·Wall Street's wire, on your screen.
LGND· Ligand Pharmaceuticals IncorporatedTVTX· Travere Therapeutics Inc.
Health Care